Aluminum hydroxide

Identification

Name
Aluminum hydroxide
Accession Number
DB06723
Type
Small Molecule
Groups
Approved
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Structure
Thumb
Synonyms
  • Aluminium hydroxide
  • Aluminium hydroxide gel, dried
  • Aluminium hydroxide, dried
  • Aluminum hydroxide gel, dried
  • Aluminum hydroxide, dried
  • Dried aluminium hydroxide
  • Dried aluminum hydroxide gel
External IDs
NSC-664400
Product Ingredients
IngredientUNIICASInChI Key
Algeldrate03J11K103C1330-44-5SMYKVLBUSSNXMV-UHFFFAOYSA-K
Almagate568Z59H7ZJ66827-12-1MTEOMEWVDVPTNN-UHFFFAOYSA-E
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alu-tab Tab 600mgTablet600 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada
Aluminum HydroxideGel320 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralAtlantic Biologicals Corps.2005-02-01Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralRugby2005-02-01Not applicableUs
Derma GranOintment.275 g/100gTopicalMckesson Medical Surgical2013-11-12Not applicableUs
DermadroxOintment1.356 g/113gTopicalGeritrex Llc2013-01-30Not applicableUs
Dermagran OintmentOintment0.275 %TopicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada
DermaMedOintment2 g/100gTopicalDermarite Industries, Llc2016-10-18Not applicableUs
International/Other Brands
AlternaGel (J&J-Merck) / Alu-Cap (3M) / Amphojel (Wyeth)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Gone AntacidAluminum hydroxide (95 mg/15mL) + Magnesium carbonate (358 mg/15mL)LiquidOralMajor2004-12-30Not applicableUs
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralMajor2014-06-06Not applicableUs
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralAvera Mc Kennan Hospital2015-07-09Not applicableUs
Acidex Tc Oral SuspensionAluminum hydroxide (600 mg) + Magnesium Hydroxide (300 mg)SuspensionOralGen Drug Company Ltd.Not applicable1997-05-30Canada
Advanced Antacid CherryAluminum hydroxide (400 mg/5mL) + Dimethicone (40 mg/5mL) + Magnesium Hydroxide (400 mg/5mL)LiquidOralMc Kesson2012-06-01Not applicableUs
Advanced Antacid Regular StrengthAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium Hydroxide (200 mg/5mL)LiquidOralSunmark (Mckesson)2012-06-01Not applicableUs
AHC Premium Intense Contour BalmAluminum hydroxide (.45 g/50mL) + Adenosine (.02 g/50mL) + Aluminium tristearate (.04 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 cst) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (.96 g/50mL)CreamTopicalCarver Korea Co.,Ltd.2014-01-15Not applicableUs
Alka Phenyl TabAluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg) + Phenylbutazone (100 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabAluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg) + Phenylbutazone (100 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
AlmaconeAluminum hydroxide (200 mg/1) + Dimethicone (25 mg/1) + Magnesium Hydroxide (200 mg/1)Tablet, chewableOralRemedy Repack2015-06-302017-02-22Us
Categories
UNII
5QB0T2IUN0
CAS number
21645-51-2
Weight
Average: 78.0036
Monoisotopic: 77.989757403
Chemical Formula
AlH3O3
InChI Key
WNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]

Pharmacology

Indication

For relief of heartburn and acid indigestion.

Structured Indications
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.

Mechanism of action

Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Absorption

Approximately 17-30% of the aluminum chloride formed is absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Not metabolized.

Route of elimination

Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminum hydroxide.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AcepromazineAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
AlimemazineAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAluminum hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
AmphetamineAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Aluminum hydroxide.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Aluminum hydroxide.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Aluminum hydroxide.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Aluminum hydroxide.Investigational
AtazanavirAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
BenzphetamineAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aluminum hydroxide.Approved
BL-1020Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
CalcidiolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcipotriol.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminum hydroxide.Withdrawn
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
ChlorphentermineAluminum hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineAluminum hydroxide can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineAluminum hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Cholic AcidAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
CinoxacinAluminum hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Aluminum hydroxide.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Aluminum hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Aluminum hydroxide.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Aluminum hydroxide.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.Approved
DasatinibAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aluminum hydroxide.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Aluminum hydroxide.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aluminum hydroxide.Approved
DemeclocyclineAluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Aluminum hydroxide.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminum hydroxide.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aluminum hydroxide.Vet Approved
DexmethylphenidateAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aluminum hydroxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aluminum hydroxide.Approved
DihydrotachysterolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.Approved
Dipotassium phosphateAluminum hydroxide can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.Approved
DoxercalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol.Approved
DoxycyclineAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Aluminum hydroxide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aluminum hydroxide.Approved
EnoxacinAluminum hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Aluminum hydroxide.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Aluminum hydroxide.Approved
ErgocalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Aluminum hydroxide.Approved
EthambutolAluminum hydroxide can cause a decrease in the absorption of Ethambutol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Ferric CarboxymaltoseAluminum hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateAluminum hydroxide can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminum hydroxide.Approved
FleroxacinAluminum hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Aluminum hydroxide.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved
FlumequineAluminum hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved
FluphenazineAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Aluminum hydroxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminum hydroxide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GarenoxacinAluminum hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinAluminum hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GemifloxacinAluminum hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineAluminum hydroxide may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinAluminum hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Aluminum hydroxide.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
HydroxyamphetamineAluminum hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum hydroxide.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Iofetamine I-123Aluminum hydroxide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronAluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAluminum hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAluminum hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Aluminum hydroxide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aluminum hydroxide.Approved
LevofloxacinAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.Approved
LisdexamfetamineAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Aluminum hydroxide.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Aluminum hydroxide.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aluminum hydroxide.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Aluminum hydroxide.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Aluminum hydroxide.Approved, Investigational
MephedroneAluminum hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MequitazineAluminum hydroxide can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.Approved
MesoridazineAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
MethotrimeprazineAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineAluminum hydroxide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.Experimental
MidomafetamineAluminum hydroxide may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Aluminum hydroxide is combined with Misoprostol.Approved
MMDAAluminum hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MoricizineAluminum hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAluminum hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Aluminum hydroxide.Investigational
NemonoxacinAluminum hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
NorfloxacinAluminum hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminum hydroxide.Investigational
Oxolinic acidAluminum hydroxide can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.Approved
ParicalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.Approved
PazufloxacinAluminum hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinAluminum hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aluminum hydroxide.Approved
PerazineAluminum hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidAluminum hydroxide can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidAluminum hydroxide can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Potassium CitratePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Vet Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Aluminum hydroxide.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminum hydroxide.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Aluminum hydroxide.Experimental, Investigational
ProchlorperazineAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropericiazineAluminum hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineAluminum hydroxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinAluminum hydroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Aluminum hydroxide.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Aluminum hydroxide.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Aluminum hydroxide.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aluminum hydroxide.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aluminum hydroxide.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
RitobegronAluminum hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinAluminum hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
RufloxacinAluminum hydroxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
SitafloxacinAluminum hydroxide can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium CitrateSodium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
Sodium glycerophosphateAluminum hydroxide can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateAluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
SparfloxacinAluminum hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Aluminum hydroxide.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Aluminum hydroxide.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Aluminum hydroxide.Approved
TemafloxacinAluminum hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiazinamAluminum hydroxide can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineAluminum hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineAluminum hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aluminum hydroxide.Approved
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminum hydroxide.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
TriethylenetetramineAluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAluminum hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminum hydroxide.Approved, Experimental
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Aluminum hydroxide.Approved
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Vitamin CVitamin C can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Nutraceutical
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Food Interactions
Not Available

References

Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.

US4915930
General References
Not Available
External Links
KEGG Compound
C13391
PubChem Compound
10176082
PubChem Substance
175427087
ChemSpider
8351587
ChEBI
33130
ChEMBL
CHEMBL1200706
ATC Codes
A02AB01 — Aluminium hydroxide
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 84:04.92 — Miscellaneous Local Anti-infectives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionFlu caused by Influenza1
1CompletedPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections6
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentToxic Shock Syndrome Staphylococcal1
1RecruitingBasic ScienceGastroesophageal Reflux Disease1
1RecruitingPreventionExposure to Hepatitis B Virus1
1WithdrawnPreventionCoronavirus (SARS-CoV)1
1WithdrawnPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1WithdrawnPreventionSevere Acute Respiratory Syndrome1
1, 2CompletedPreventionFlu caused by Influenza3
2CompletedNot AvailableAcid Reflux Disease / GERD / Heartburn / Regurgitation1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableUnknown StatusPreventionPeptic Ulcers / Ulcer Complications1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral600 mg
GelOral320 mg/5mL
LiquidOral320 mg/5mL
OintmentTopical.275 g/100g
OintmentTopical1.356 g/113g
OintmentTopical0.275 %
OintmentTopical2 g/100g
SolutionOral
PowderOral
Tablet, chewableOral
TabletOral
GranuleOral
CreamTopical
LiquidTopical
LiquidOral
SuspensionOral
TabletOral; Other
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)4.07ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal oxoanionic compounds
Sub Class
Post-transition metal hydroxides
Direct Parent
Post-transition metal hydroxides
Alternative Parents
Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Post-transition metal hydroxide / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
aluminium hydroxides (CHEBI:33130)

Drug created on August 09, 2010 11:11 / Updated on November 22, 2017 12:41